Donor fecal microbiota transplantation ameliorates intestinal graft-versus-host disease in allogeneic hematopoietic cell transplant recipients
Yannouck F. van Lier, Mark Davids, Nienke J.E. Haverkate, Pieter F. de Groot, Marjolein L. Donker, Ellen Meijer, Floor Heubel-Moenen, Erfan Nur, Sacha Zeerleder, Max Nieuwdorp, Bianca Blom, Mette D. Hazenberg
Abstract
species. In 6 of the 10 responding donor FMT recipients, immunosuppressant drug therapy was successfully tapered. Durable remission of steroid-refractory or steroid-dependent GvHD after donor FMT was associated with improved survival at 24 weeks after donor FMT. This study highlights the potential of donor FMT as a treatment for steroid-refractory or steroid-dependent GvHD, but larger clinical trials are needed to confirm the safety and efficacy of this procedure.
Topics & Concepts
Fecal bacteriotherapyGraft-versus-host diseaseTransplantationHematopoietic stem cell transplantationFecesImmunologyHematopoietic cellGut floraDiseaseHost (biology)BiologyMedicineHaematopoiesisMicrobiologyStem cellAntibioticsInternal medicineClostridium difficileEcologyGeneticsHematopoietic Stem Cell TransplantationClostridium difficile and Clostridium perfringens researchChildhood Cancer Survivors' Quality of Life